We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat
- Posted on February 4, 2026
- By CNBC
- 2 Views
We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing triple-digit growth.
